Brexucabtagene autoleucel

布瑞基奥仑赛

Report date: 2025/10/10 14:38:01

Base Information

Drug NameBrexucabtagene autoleucel
Drug Alias NameTecartusKTE-X19FKC-889
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Source of cells > Peripheral blood-derivedCell and gene therapy > Cell therapy > Donor > Autologous +[4] 
Mechanisms of ActionAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, Mantle-CellLymphoma, Non-HodgkinPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma +[5] 
Global Approved IndicationsLymphoma, Mantle-Cell
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2020/07/24
Country/TerritoryCzechiaBelgiumCanada +[13] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesKite Pharma IncGilead Sciences Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesFosun Kite Biotechnology Co., Ltd.Kite PharmaKite Pharma Eu Bv +[6] 
Inactive CompaniesN/A
Active IndicationsLymphoma, Mantle-CellLymphoma, Non-HodgkinPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeL01X
Related LinksWikipediaDrugBank